Lisata Therapeutics (LSTA) Competitors $2.59 +0.12 (+4.86%) Closing price 08/22/2025 03:58 PM EasternExtended Trading$2.60 +0.01 (+0.39%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. CELU, ENTX, OKYO, QNCX, CRVO, ORMP, ABOS, ATRA, PMVP, and ELUTShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Celularity (CELU), Entera Bio (ENTX), OKYO Pharma (OKYO), Quince Therapeutics (QNCX), CervoMed (CRVO), Oramed Pharmaceuticals (ORMP), Acumen Pharmaceuticals (ABOS), Atara Biotherapeutics (ATRA), PMV Pharmaceuticals (PMVP), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Celularity Entera Bio OKYO Pharma Quince Therapeutics CervoMed Oramed Pharmaceuticals Acumen Pharmaceuticals Atara Biotherapeutics PMV Pharmaceuticals Elutia Lisata Therapeutics (NASDAQ:LSTA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability. Which has stronger valuation and earnings, LSTA or CELU? Lisata Therapeutics has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M22.69-$19.99M-$2.23-1.16Celularity$54.22M1.67-$57.89M-$2.65-1.43 Is LSTA or CELU more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Lisata Therapeutics' return on equity of -69.68% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -69.68% -59.44% Celularity -106.77%-271.88%-42.82% Which has more volatility and risk, LSTA or CELU? Lisata Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Does the media favor LSTA or CELU? In the previous week, Celularity had 8 more articles in the media than Lisata Therapeutics. MarketBeat recorded 9 mentions for Celularity and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.50 beat Celularity's score of 0.37 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lisata Therapeutics Positive Celularity Neutral Do analysts rate LSTA or CELU? Lisata Therapeutics presently has a consensus price target of $23.50, indicating a potential upside of 807.34%. Celularity has a consensus price target of $6.00, indicating a potential upside of 58.31%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Lisata Therapeutics is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in LSTA or CELU? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 22.1% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryLisata Therapeutics beats Celularity on 11 of the 16 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.63M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-1.1620.8831.1026.05Price / Sales22.69342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book1.098.129.536.61Net Income-$19.99M-$54.72M$3.26B$265.56M7 Day Performance2.37%2.63%2.10%1.97%1 Month Performance-2.26%2.78%2.81%-0.36%1 Year Performance-13.67%11.01%30.56%19.03% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.1964 of 5 stars$2.59+4.9%$23.50+807.3%-8.5%$21.63M$1M-1.1630Analyst ForecastCELUCelularity0.7274 of 5 stars$3.70-11.0%$6.00+62.4%+21.7%$88.50M$54.22M-1.39220News CoverageAnalyst UpgradeENTXEntera Bio1.176 of 5 stars$1.90-5.0%$10.00+426.3%+13.5%$87.40M$166K-7.3620Short Interest ↑OKYOOKYO Pharma2.4694 of 5 stars$2.31-4.1%$7.00+203.0%+127.9%$86.88MN/A0.007Gap DownQNCXQuince Therapeutics3.1227 of 5 stars$1.61-3.6%$8.14+405.8%+154.3%$86.47MN/A-1.4860CRVOCervoMed2.43 of 5 stars$9.24-6.1%$23.71+156.8%-41.8%$85.79M$9.74M-3.554Analyst RevisionORMPOramed Pharmaceuticals0.7973 of 5 stars$2.07-0.5%N/A-13.4%$84.55M$2M-5.9110News CoverageABOSAcumen Pharmaceuticals3.0735 of 5 stars$1.40-2.4%$6.33+354.0%-45.6%$84.50MN/A-0.6120ATRAAtara Biotherapeutics4.6717 of 5 stars$11.78+2.6%$21.00+78.3%+73.3%$83.22M$128.94M-27.57330News CoveragePositive NewsInsider TradeAnalyst RevisionPMVPPMV Pharmaceuticals2.3266 of 5 stars$1.57+1.0%$5.50+250.3%-3.3%$83.19MN/A-1.0050Positive NewsELUTElutia3.8774 of 5 stars$1.99-1.5%$8.00+302.0%-47.9%$82.64M$23.68M-1.90180Analyst Revision Related Companies and Tools Related Companies Celularity Competitors Entera Bio Competitors OKYO Pharma Competitors Quince Therapeutics Competitors CervoMed Competitors Oramed Pharmaceuticals Competitors Acumen Pharmaceuticals Competitors Atara Biotherapeutics Competitors PMV Pharmaceuticals Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access